Kestra Medical Technologies, Ltd. filed a Form S-1 registration statement for an initial public offering on 2025-02-10. It has amended it 2 times. It filed its final prospectus on 2025-12-03, at a public offering price of $23.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common shares are listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “KMTS.” On December 2, 2025, the last reported sale price of our common shares on Nasdaq was $23.01 per share.From the 424B4 filed 2025-12-03
Offering price
The as adjusted consolidated balance sheet data give further effect to our issuance and sale of 6,000,000 common shares in this offering at the public offering price of $23.00 per common share, after deducting underwriting discounts and commissions and estimated offering costs incurred by us.From the 424B4 filed 2025-12-03
Underwriters
Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as representatives of the underwriters named below.From the 424B4 filed 2025-12-03
Use of proceeds
We intend to use the net proceeds from this offering, together with our existing cash, to scale up our commercial organization through the hiring of additional sales representatives, sales team leadership and clinical care specialists, as well as continued investments in our fleet of devices, supply chain and revenue cycle management capabilities.From the 424B4 filed 2025-12-03
Revenue
For the three months ended July 31, 2025, we generated revenue of $19.4 million, compared to revenue of $12.8 million for the three months ended July 31, 2024, representing 52.0% quarter-over-quarter growth.From the S-1 filed 2025-12-01
Net loss or income
We incurred net losses of $25.8 million and $20.3 million for the three months ended July 31, 2025 and 2024, respectively.From the S-1 filed 2025-12-01
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-02-10 | Registration statement filed | S-1 |
| 2025-02-26 | Registration statement amended | S-1/A |
| 2025-03-03 | Registration statement amended | S-1/A |
| 2025-03-06 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-12-01 | Registration statement filed | S-1 |
| 2025-12-03 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Kestra Medical Technologies, Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.